Skip to main content
Clinical Trials/NCT06001073
NCT06001073
Recruiting
Not Applicable

Prognosis Prediction System of Patients With Cardiovascular and Cerebrovascular Diseases Based on Multi-omics (PROSPECT): a National, Multicenter, Retrospective-prospective, Cohort Study

First Affiliated Hospital Xi'an Jiaotong University1 site in 1 country25,000 target enrollmentDecember 5, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coronary Artery Disease
Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Enrollment
25000
Locations
1
Primary Endpoint
Change of MACCE
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

The etiology and specific pathogenesis of many cardiovascular diseases such as coronary atherosclerosis, cardiomyopathy, atrial fibrillation, and stroke are still unclear. Improving diagnosis and treatment, clarifying the pathogenesis, and providing scientific basis for the prevention and treatment are hot research topics in the study of cardiovascular and cerebrovascular diseases. This study intends to collect clinical data and biological specimen data of patients with cardiovascular and cerebrovascular diseases who meet the inclusion and exclusion criteria, and use multi-omics technology to deeply understand the pathogenic mechanisms of cardiovascular and cerebrovascular diseases and provide new ideas for specific and individualized treatment of patients with cardiovascular and cerebrovascular diseases, to construct early predictive prognostic models and provide a basis for effective treatment of clinical practice in patients with cardiovascular and cerebrovascular diseases.

Detailed Description

Cardiovascular and cerebrovascular diseases refer to ischemic and hemorrhagic diseases of the heart, brain and body tissues caused by hyperlipidemia, blood viscosity, atherosclerosis, hypertension, etc. It is one of the major public health problems in the world. The etiology and specific pathogenesis of many cardiovascular diseases such as coronary atherosclerosis, cardiomyopathy, atrial fibrillation, and stroke are still unclear. Improving diagnosis and treatment, clarifying the pathogenesis, and providing scientific basis for the prevention and treatment are hot research topics in the study of cardiovascular and cerebrovascular diseases. This study intends to collect clinical data and biological specimen data of patients with cardiovascular and cerebrovascular diseases who meet the inclusion and exclusion criteria, and use multi-omics technology to deeply understand the pathogenic mechanisms of cardiovascular and cerebrovascular diseases and provide new ideas for specific and individualized treatment of patients with cardiovascular and cerebrovascular diseases, to construct early predictive prognostic models and provide a basis for effective treatment of clinical practice in patients with cardiovascular and cerebrovascular diseases.

Registry
clinicaltrials.gov
Start Date
December 5, 2022
End Date
December 31, 2028
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients who are regularly visited and followed up in the appropriate patient; department.
  • All patients met at least one of the following diagnostic criteria for cardiovascular and cerebrovascular diseases:
  • coronary artery disease group;
  • arrhythmia group;
  • heart valve disease group;
  • aortic dissection group;
  • cardiac masses group;
  • myocarditis group;
  • hypertension group;
  • cardiomyopathy group;

Exclusion Criteria

  • Age \<3 years or \>80 years old;
  • Pregnant and lactating women;
  • The patient declined to provide informed consent to participate in the study;
  • None of the above was met, but the patient was temporarily unable to sign the informed consent form due to coma and other reasons, and no legal representative signed it instead. Depending on the patient's condition, the patient may not be able to regain consciousness and sign the informed consent form.

Outcomes

Primary Outcomes

Change of MACCE

Time Frame: Through study completion, up to 5 years.

Major adverse cardiovascular and cerebrovascular events, a composite of all-cause mortality, myocardial infarction, coronary revascularization, and stroke.

Secondary Outcomes

  • Incidence of myocardial infarction(Through study completion, up to 5 years.)
  • Change of all-cause mortality(Through study completion, up to 5 years.)
  • Incidence of stroke(Through study completion, up to 5 years.)
  • Incidence of coronary revascularization.(Through study completion, up to 5 years.)

Study Sites (1)

Loading locations...

Similar Trials